Different TAAs were translated into clinical trials for the treatment of CRC, including carcinoembryonic antigen (CEA), EGFR, mesothelin (MSLN), mucin 1 (MUC1), Natural killer group 2 member D (NKG2D) and its ligand, human epidermal growth factor receptor 2 (HER2), c-met, and CD133 (Table 2). The gene discussed is MUC1; the disease is colorectal carcinoma.